Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025 Conference
Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% reduction in anti-VEGF IVT treatment in fellow eyes of bilateral disease patients Maintenance of BCVA and reduction of CST in these previously treated patients Migaldendranib therapy obviates or reduces the need for more invasive in-the-eye injections REDWOOD … Read more